Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 26, 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
A re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan resulted in an increase in the notional allocation of Ordinary share ADRs on January 22, 2010. The transaction price was $40.76 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 22, 2010 (Notification date: January 26, 2010).
- Transaction Price: $40.76 per ADR.
- Involved Parties: Dr M M Slaoui (15 ADRs), Mr W C Louv (8 ADRs), Dr D Pulman (11 ADRs).
- Plan Type: US Retirement Savings Plan (notional investment in GSK Ordinary share ADRs).